Paper Details

  1. Home
  2. Paper Details

Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: Results of the 2PRECISE study.

Author: BachelezHervé, BurdenA David, Chaouche-TeyaraKamel, MrowietzUlrich, OrsenigoRoberto, RisslerMichael, SiederChristian

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Secukinumab 300 mg showed benefit in improving Palmoplantar Psoriasis Area and Severity Index (PPPASI) scores and quality of life in patients with palmoplantar pustular psoriasis (PPP) over 52 weeks.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Palmoplantar pustular psoriasis (PPP) is a debilitating disease of the palms and/or soles that is resistant to treatment. Secukinumab, an anti-interleukin 17A monoclonal antibody, is highly efficacious in the treatment of moderate-to-severe psoriasis. OBJECTIVE: The primary objective wa...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.jaad.2019.01.066

データ提供：米国国立医学図書館（NLM）

Secukinumab for Palmoplantar Pustular Psoriasis: A New Oasis in the Treatment Desert

[Palmoplantar pustular psoriasis (PPP)] can be a debilitating condition, often resistant to conventional treatments. This research explores the potential of [seukinumab] as a new treatment option for this challenging skin condition. The authors designed a [phase 3b multicenter, randomized, double-blind, placebo-controlled study] to compare the effectiveness of seukinumab at two different dosages (300 mg and 150 mg) to placebo. They evaluated the participants' responses using the [Palmoplantar Psoriasis Area and Severity Index (PPPASI)] and the [Dermatology Life Quality Index]. The results indicated that [seukinumab 300 mg] demonstrated significant improvements in PPPASI scores and overall quality of life compared to placebo.

A Promising Path for PPP Patients

The study shows that [seukinumab 300 mg] holds promise as a [valuable treatment option] for patients with PPP. It significantly improved [PPPASI scores] and [quality of life] compared to placebo, offering a new ray of hope for those seeking relief from this challenging condition.

Navigating the PPP Landscape

While the study highlights the potential benefits of [seukinumab], it's important to remember that [individual responses to medications] can vary. It's essential to consult with your doctor and discuss treatment options to find the best approach for managing your PPP. This research provides a valuable stepping stone towards more effective and personalized treatment strategies for PPP patients. It's like finding a hidden oasis in the vast desert of skin conditions, offering a new path towards clearer and healthier skin.

Dr. Camel's Conclusion

This study sheds light on the potential of secukinumab as a new treatment for palmoplantar pustular psoriasis, offering hope for those struggling with this challenging condition. The research emphasizes the importance of personalized treatment approaches, considering individual responses to medications and seeking expert medical guidance for optimal outcomes. While the desert of skin conditions might seem vast, this research suggests that new pathways are emerging, paving the way for clearer and healthier skin.

Date :
  1. Date Completed 2019-04-29
  2. Date Revised 2019-12-10
Further Info :

Pubmed ID

30716404

DOI: Digital Object Identifier

10.1016/j.jaad.2019.01.066

Related Literature

Article Analysis
・Effective treatment of psoriasis
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.